Proactive Skin Care Halves Toxicity in EGFR NSCLC Trial

Got story updates? Submit your updates here. ›

A new research perspective published in Oncoscience summarizes interim findings from the phase II COCOON trial, which tested whether a structured dermatologic prophylaxis regimen could reduce skin toxicities in patients receiving first-line amivantamab plus lazertinib for EGFR-mutant non-small cell lung cancer. The COCOON regimen, which included oral doxycycline or minocycline, ceramide-based moisturization, chlorhexidine nail care, and topical clindamycin, reduced the incidence of grade ≥2 dermatologic adverse events from 76.5% with standard reactive care to 38.6% with prophylaxis.

Why it matters

The COCOON results emphasize the clinical value of anticipating EGFR inhibitor-related toxicities through multidisciplinary supportive care. Straightforward, low-cost interventions can improve tolerability and maintain dose intensity, while future clinical practice updates will likely incorporate this kind of proactive supportive care approach more broadly.

The details

The commentary describes a prophylactic protocol that included oral doxycycline or minocycline, ceramide-based moisturization, chlorhexidine nail care, and topical clindamycin. In the interim analysis, the COCOON regimen reduced moderate-to-severe dermatologic adverse events, with the incidence of grade ≥2 events falling from 76.5% with standard reactive care to 38.6% with prophylaxis. The paper also reports reductions in grade ≥3 events and treatment discontinuations.

• The research perspective was published in Volume 13 of Oncoscience on March 11, 2026.
• The COCOON trial is a phase II study.

What’s next

Future clinical practice updates will likely incorporate this kind of proactive supportive care approach more broadly.